Detailed price information for Guardant Health Inc (GH-Q) from The Globe and Mail including charting and trades.

Diagnostics company Guardant Health (NASDAQ:GH) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 30.9% ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its partnership with actor and ...

The American Cancer Society (ACS) today announced a new partnership with Guardant Health (Nasdaq: GH), a leading precision ...

Guardant Health raised its FY2025 sales guidance from $880.00 million-$890.00 million to $915.00 million-$925.00 million.

James Van Der Beek is sharing the subtle colorectal cancer symptom he ignored before his shocking diagnosis. “There wasn’t ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the upcoming Canaccord Genuity 45 th Annual Growth Conference in Boston, MA.

James Van Der Beek has just woken up from a nap as he hops on a Microsoft Teams call.

Exact Sciences is paying $75 million for exclusive rights to a blood-based "liquid biopsy" screening test from rival firm ...

James Van Der Beek and Guardant are partnering for a campaign focused on colorectal cancer. Guardant Health announced a ...

Guardant Health reports strong Q2 2025 results with 31% revenue growth, raised guidance, and momentum in oncology and Shield screening.

Guardant Health partners with actor James Van Der Beek to promote early colorectal cancer screening through the Shield blood ...